In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol ...

Discover a novel technology to standardize purification across a broad range of microbial proteins that accelerates and ...

Downstream processing can be the cause of a bottleneck in manufacturing, particularly for complex biologics, leading to a ...

Commercializing sustainability hinges on reframing it as risk mitigation and competitive advantage, supported by medium-to-long-term resilience planning and co-creation with suppliers rather than ...

Christy Owings, Thermo Fisher, discusses how customs delays and import complexity risk clinical trial supply chains in Latin America. Christy Owings, Vice President and General Manager of the Americas ...

Tara Dougal, event director for pharma at Informa Markets and head of CPHI Milan, previews the 2026 show in an interview with ...

Novartis obtained portfolio-level options for exclusive rights to Hybrozyme-enabled SC formulations, with economics up to ...

Extending CAR T beyond cancer alters risk–benefit calculus, because chronic autoimmune populations have alternative therapies ...

The FDA approves zilganersen, the first disease-modifying Alexander disease therapy, offering rare disease developers a trial ...

Vice President and General Manager, Clinical Trials, Americas, at Thermo Fisher Scientific. With more than 20 years of ...

On August 31, 2026, Eli Lilly announced it has entered a definitive agreement to acquire Merida Biosciences, a biotechnology ...

The FDA cleared four notable therapies within the same week in late August, spanning infectious disease, cardiometabolic care ...